<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403516</url>
  </required_header>
  <id_info>
    <org_study_id>Dextenza in Pterygium Surgery</org_study_id>
    <nct_id>NCT04403516</nct_id>
  </id_info>
  <brief_title>Dextenza in Pterygium Surgery</brief_title>
  <official_title>Dextenza in Pterygium Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michelle Rhee MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Eye Specialists</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      DEXTENZA for the treatment of post-surgical pain and inflammation compared to standard of
      care topical prednisolone acetate 1% in patients who undergo pterygium surgery (excision of
      pterygium with conjunctival autograft)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients who undergo pterygium surgery, eyes will be randomized to receive either DEXTENZA
      or topical prednisolone acetate 1%.15 eyes will receive a Dextenza insertion into both the
      upper and lower puncta at the time of surgery, followed by at postoperative month 1 visit
      institution of topical prednisolone acetate 1% bid x 2 weeks then qd x 2 weeks then
      discontinued. 15 eyes will receive starting on postoperative day 1 topical prednisolone
      acetate 1% q2 hours x 2 weeks then qid for 2 weeks then bid for 2 weeks then qd for 2 weeks
      then discontinued.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>In patients who undergo pterygium surgery, eyes will be randomized to receive either DEXTENZA (15 eyes) into both the upper and lower puncta at the time of surgery, followed by at postoperative month 1 visit institution of topical prednisolone acetate 1% bid x 2 weeks then qd x 2 weeks then discontinued or receive topical prednisolone acetate 1% (15 eyes) q2 hours x 2 weeks then qid for 2 weeks then bid for 2 weeks then qd for 2 weeks then discontinued.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction-comfort and convenience</measure>
    <time_frame>Assessed on Post-Op Day 1</time_frame>
    <description>Assessed by patient reported questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction-comfort and convenience</measure>
    <time_frame>Assessed on Week 1</time_frame>
    <description>Assessed by patient reported questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction-comfort and convenience</measure>
    <time_frame>Assessed on Month 1</time_frame>
    <description>Assessed by patient reported questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction-comfort and convenience</measure>
    <time_frame>Assessed on Month 3</time_frame>
    <description>Assessed by patient reported questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction-comfort and convenience</measure>
    <time_frame>Assessed on Month 6</time_frame>
    <description>Assessed by patient reported questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the degree of conjunctival hyperemia</measure>
    <time_frame>Assessed on Week 1</time_frame>
    <description>Assessed by clinical external photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the degree of conjunctival hyperemia</measure>
    <time_frame>Assessed on Month 1</time_frame>
    <description>Assessed by clinical external photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the degree of conjunctival hyperemia</measure>
    <time_frame>Assessed on Month 2</time_frame>
    <description>Assessed by clinical external photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the degree of conjunctival hyperemia</measure>
    <time_frame>Assessed on Month 3</time_frame>
    <description>Assessed by clinical external photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the degree of conjunctival hyperemia</measure>
    <time_frame>Assessed on Month 6</time_frame>
    <description>Assessed by clinical external photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of days for corneal re-epithelialization</measure>
    <time_frame>Assessed on Post-Op Day 1</time_frame>
    <description>As evaluated by slit lamp examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of days for corneal re-epithelialization</measure>
    <time_frame>Assessed on Week 1</time_frame>
    <description>As evaluated by slit lamp examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of days for corneal re-epithelialization</measure>
    <time_frame>Assessed on Month 1</time_frame>
    <description>As evaluated by slit lamp examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of pterygium</measure>
    <time_frame>Assessed at Month 1</time_frame>
    <description>As measured by yes or no on recurrence; external eye examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of pterygium</measure>
    <time_frame>Assessed at Month 2</time_frame>
    <description>As measured by yes or no on recurrence; external eye examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of pterygium</measure>
    <time_frame>Assessed at Month 3</time_frame>
    <description>As measured by yes or no on recurrence; external eye examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of pterygium</measure>
    <time_frame>Assessed at Month 6</time_frame>
    <description>As measured by yes or no on recurrence; external eye examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>DEXTENZA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Pterygium DEXTENZA Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Prednisolone Acetate 1% Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Pterygium Topical Prednisolone Acetate 1% Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Intracanalicular Insert, 0.4mg</intervention_name>
    <description>To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.</description>
    <arm_group_label>DEXTENZA Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1%</intervention_name>
    <description>To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.</description>
    <arm_group_label>Topical Prednisolone Acetate 1% Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A patient's study eye must meet the following criteria to be eligible for inclusion in the
        study:

        â€¢ Age of at least 18 years with primary pterygia

        Exclusion Criteria:

        A patient who meets any of the following criteria will be excluded from the study:

          -  Glaucoma

          -  Ocular hypertension

          -  Prior conjunctival surgery

          -  Other uncontrolled ocular disease

          -  Ocular surgery in either eye within 3 months

          -  Use of eye drops other than postoperative medications and artificial tears
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle K Rhee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Eye Specialists</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle K Rhee, MD</last_name>
    <phone>646-543-2015</phone>
    <email>drmichellerhee@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York Eye Specialists</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michelle K Rhee, MD</last_name>
      <phone>646-543-2015</phone>
      <email>drmichellerhee@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michelle K Rhee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>New York Eye Specialists</investigator_affiliation>
    <investigator_full_name>Michelle Rhee MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

